

CLAIMS

1. An anticancer agent comprising BL-angiostatin as an active ingredient thereof.
- 5 2. The anticancer agent according to claim 1 wherein the BL-angiostatin is derived from a mammal.
3. The anticancer agent according to claim 1 or 2 wherein the BL-angiostatin is selected from a group consisting of Glu¹-Ser⁴⁴¹, Glu¹-Val⁴⁴⁹, Phe⁷⁵-Ser⁴⁴¹ and Phe⁷⁵-Val⁴⁴⁹ fragments 10 of human plasminogen.
4. A method for producing the BL-angiostatin according to claim 1 comprising the steps of:
equilibrating an affinity trap reactor, in which bacillolysin MA and lysine are immobilized on agarose gel,
15 with a buffer;
adding serum treated with citric acid;
washing with a buffer containing sodium chloride; and
eluting with 6-aminohexanoic acid; wherein,
the buffer does not contain isopropyl alcohol.